Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

uch statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire and implementing our new SAP enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and de
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)...   Y-Prime, Inc ., announced today that ... in Philadelphia , June 15-18 ... allows influential decision makers from the Biotech industry ... emerging technologies such as YPrime. "Our ... implementation and management of Interactive Response Technology (IRT) ...
(Date:6/2/2015)... MARLBOROUGH, Mass. , June 2, 2015 ... ), a biotechnology company focused on discovering ... areas of dermatology and ophthalmology, today announced that ... Development Officer, will present at the 23 ... This six-day world congress will include in-depth ...
(Date:6/2/2015)... MGB Biopharma at the ... MGB Biopharma, a biopharmaceutical company developing ... the major global problem of antibiotic resistance - ... (IV) formulation of MGB-BP-3, designed for the treatment of ... The intravenous formulation of MGB-BP-3 is currently in ...
(Date:6/1/2015)... DUBLIN , June 1, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/jpslnm/oxidative_stress ) has announced the addition of ... Product (Consumables, Instruments, Services), Test Type (Indirect, ... Chromatography, Flow Cytometry), End Users - Global ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
Breaking Biology Technology:YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2
... , , NEW YORK, Aug. 5 ... a biopharmaceutical company focused on the acquisition, development and ... treatment of life-threatening diseases, including renal disease and cancer ... quarter ended June 30, 2009. , , ...
... , , , SADDLE ... a leading provider of sales and marketing support to U.S. pharmaceutical companies, ... Recent highlights include: , , , Four ... Signed agreement with The Medical Affairs Company (TMAC(R)) to enhance ...
... , SAN DIEGO, Aug. 5 Orexigen(R) Therapeutics, Inc. ... of obesity, today announced that the Company will be speaking at the ... follows: , , ... a.m. Eastern, Location: InterContinental Boston, London Room, ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 6PDI Reports 2009 Second Quarter Financial Results 2PDI Reports 2009 Second Quarter Financial Results 3PDI Reports 2009 Second Quarter Financial Results 4PDI Reports 2009 Second Quarter Financial Results 5PDI Reports 2009 Second Quarter Financial Results 6PDI Reports 2009 Second Quarter Financial Results 7PDI Reports 2009 Second Quarter Financial Results 8PDI Reports 2009 Second Quarter Financial Results 9
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/21/2015)... 2015 The Sync Project™ , a ... health, today announced a collaborative partnership with Berklee,s ... center on collaboration on original research, joint course development ... the collaboration, The Sync Project and BerkleeICE are exploring ... in the 2015-2016 academic year.  The ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... pre-Columbian Amazonian populations settled in large numbers across Amazonia ... take to be ‘natural.' , This view has become ... in a recent paper from Dr. Mark Bush of ... research may rekindle a debate has major implications for ...
... an ancient wheat variety have led to a major advance ... of papers published in the journal Plant Physiology researchers describe ... genes work by excluding salt from different parts of the ... The discovery of the two genes is the subject of ...
... believe they have discovered by chance a new ... of the esophagus, liver and skin. Early work ... proliferator-activated receptor-gamma (PPARgamma) inhibitors may have an unexpected ... the journal International Cancer Research. Furthermore, the new ...
Cached Biology News:Paper challenges 1491 Amazonian population theories 2Paper challenges 1491 Amazonian population theories 3Paper challenges 1491 Amazonian population theories 4Ancient genes used to produce salt-tolerant wheat 2Gut research yields new anti-cancer approach 2Gut research yields new anti-cancer approach 3Gut research yields new anti-cancer approach 4
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: